A detailed history of Bank Of America Corp transactions in Opti Nose, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,211 shares of OPTN stock, worth $508. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,211
Previous 15,138 92.0%
Holding current value
$508
Previous $15,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.67 - $1.27 $9,331 - $17,687
-13,927 Reduced 92.0%
1,211 $0
Q2 2024

Aug 14, 2024

BUY
$0.82 - $1.44 $3,601 - $6,324
4,392 Added 40.87%
15,138 $15,000
Q1 2024

May 15, 2024

SELL
$1.17 - $1.94 $52,963 - $87,819
-45,268 Reduced 80.82%
10,746 $15,000
Q4 2023

Feb 14, 2024

BUY
$1.02 - $1.47 $55,717 - $80,298
54,625 Added 3932.69%
56,014 $72,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $2.05 $7,841 - $14,481
-7,064 Reduced 83.57%
1,389 $1,000
Q1 2023

May 12, 2023

BUY
$1.63 - $2.02 $5,338 - $6,615
3,275 Added 63.25%
8,453 $16,000
Q4 2022

Feb 10, 2023

BUY
$1.68 - $3.7 $7,175 - $15,802
4,271 Added 470.89%
5,178 $9,000
Q3 2022

Nov 14, 2022

SELL
$3.43 - $4.01 $1,708 - $1,996
-498 Reduced 35.44%
907 $4,000
Q2 2022

Aug 12, 2022

SELL
$1.76 - $3.82 $6,628 - $14,386
-3,766 Reduced 72.83%
1,405 $5,000
Q1 2022

May 16, 2022

SELL
$1.77 - $2.93 $29,015 - $48,031
-16,393 Reduced 76.02%
5,171 $13,000
Q4 2021

Feb 08, 2022

SELL
$1.55 - $3.1 $22,343 - $44,686
-14,415 Reduced 40.07%
21,564 $35,000
Q3 2021

Nov 15, 2021

SELL
$2.35 - $3.16 $140,078 - $188,361
-59,608 Reduced 62.36%
35,979 $108,000
Q2 2021

Sep 13, 2021

BUY
$2.91 - $3.83 $278,158 - $366,098
95,587 New
95,587 $297,000

Others Institutions Holding OPTN

About OptiNose, Inc.


  • Ticker OPTN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 83,277,504
  • Market Cap $35M
  • Description
  • OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...
More about OPTN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.